Expertise in
5
conditions

Danny Rischin

305 Grattan Street, 
Melbourne, VIC, AU 
Expertise in
5
conditions
305 Grattan Street, 
Melbourne, VIC, AU 

Overview

Danny Rischin practices practicing medicine in Melbourne, Australia.

Mr. Rischin is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Head and Neck Squamous Cell Carcinoma (HNSCC), Cervical Cancer, Human Papillomavirus Infection, and Cerebral Hypoxia.

He is actively involved in clinical research, co-authoring 175 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

305 Grattan Street, Melbourne, VIC, Australia
Other Locations
Grattan St, Parkville, VIC 3010, Australia
St Andrews Street, East Melbourne, VIC 3002, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors
A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase I/II, Open-label, Two Part Study of GSK3359609 in Combination With Tremelimumab in Participants With Selected, Advanced Solid Tumors
A Phase I/II, Open-label, Two Part Study of GSK3359609 in Combination With Tremelimumab in Participants With Selected, Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: August 28, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Tremelimumab, Docetaxel, Paclitaxel, Cetuximab
Study Phase: Phase 1/Phase 2
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Pembrolizumab
Study Phase: Phase 3
A Phase 2 Study of Tarloxotinib (TH-4000) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin
A Phase 2 Study of Tarloxotinib (TH-4000) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin
Enrollment Status: Terminated
Publish Date: January 12, 2023
Intervention Type: Drug
Study Phase: Phase 2
TROG12.01 A Randomised Trial of Weekly Cetuximab and Radiation Versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma
TROG12.01 A Randomised Trial of Weekly Cetuximab and Radiation Versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma
Enrollment Status: Unknown
Publish Date: November 18, 2022
Intervention Type: Drug, Radiation
Study Drugs: Cetuximab, Cisplatin
Study Phase: Phase 3
View 4 Less Clinical Trials

175 Total Publications

Sensorineural hearing outcomes in HPV-positive oropharyngeal cancer: a secondary analysis of the TROG 12.01 randomized trial (SHOUT).
Sensorineural hearing outcomes in HPV-positive oropharyngeal cancer: a secondary analysis of the TROG 12.01 randomized trial (SHOUT).
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: February 23, 2026

Frequently Asked Questions about Danny Rischin

Is Danny Rischin a top-rated expert for Head and Neck Squamous Cell Carcinoma (HNSCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Danny Rischin is classified as an Elite expert for Head and Neck Squamous Cell Carcinoma (HNSCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Danny Rischin participate in research or clinical trials?

Yes. Danny Rischin has published 175 articles and abstracts on conditions like Head and Neck Squamous Cell Carcinoma (HNSCC). You can view a list of Danny Rischin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Rischin's expertise for a condition
ConditionClose
View All 15 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile